News | January 11, 2013

FFR Startup Company Gains $250,000 Investment

Company says its technology will better analyze coronary artery blockages

January 11, 2013 — Guided Interventions LLC, a startup company developing new, easier to use fractional flow reserve (FFR) a product to help cardiologists better assess the physiological impact of coronary artery blockages, has received a $250,000 investment commitment from nonprofit venture development organization JumpStart Inc.

Guided Interventions' novel FFR guide wire provides an easier, more effective and more affordable way to obtain FFR measurements during coronary catheterization procedures.

"An FFR measurement determines the best way to treat a coronary artery blockage - whether that entails no intervention, angioplasty or angioplasty plus stenting," said Guided Interventions' CEO, Matthew Pollman.

Using FFR measurements improves the precision of these diagnoses, potentially reducing unnecessary procedures and lowering medical costs while improving patient outcomes. "As these measurements increasingly become standard practice, we believe our user-friendly FFR guide wire will be adopted widely," Pollman said.

FFR guide wires currently available to cardiologists can be difficult to guide through an artery because their powered sensors require significant structural compromises to the interior core of a guide wire. Utilizing a passive sensor, Guided Interventions' novel guide wire solution is optimized for improved maneuverability and handling.

"FFR is a relatively new and somewhat under-utilized diagnostic technology," said Mike Lang, JumpStart's venture partner. "But thanks to a great product design and a strong management team with extensive experience in medical device development and commercialization, Guided Interventions is in a good position to enter and even lead the growing FFR guide wire market."

Guided Interventions plans to use the JumpStart investment to complete development and test an initial prototype in relevant animal models. The company also intends to launch and scale its operations in Northeast Ohio within calendar year 2013, especially by hiring engineers. "Northeast Ohio's resources - including Global Cardiovascular Innovation Center, the SMART Commercialization Center and North Coast Angel Fund - are first-rate," Pollman says. "Their presence makes the region an appealing place to found and grow our company, and gives us the ability to get traction in the medical device space."

For more information: www.jumpstartinc.org

Related Content

First Prospective Registry Confirms FFR Impacts CAD Treatment Plans
News | FFR Technologies | June 17, 2019
A prospective, multicenter, multinational study examines how fractional flow reserve (FFR) can impact treatment plans...
One in Four Patients Have Residual Ischemia Following PCI
News | FFR Technologies | March 20, 2019
At the American College of Cardiology’s (ACC) annual meeting, March 16-18 in New Orleans, Philips announced the results...
HeartFlow Analysis Successfully Stratifies Heart Disease Patients at One Year
News | FFR Technologies | March 19, 2019
Late-breaking results confirm the HeartFlow FFRct (fractional flow reserve computed tomography) Analysis enables...
Abbott's Resting Full-cycle Ratio (RFR) intravascular diagnostic test is a newer type of fractional flow reserve (FFR) physiologic assessment. RFR is used to help identify significant narrowings of coronary arteries to determine the need for a stent or if a patient can be treated medically. Abbott FFR.

Abbott's Resting Full-cycle Ratio (RFR) intravascular diagnostic test is a newer type of fractional flow reserve (FFR) physiologic assessment. RFR is used to help identify significant narrowings of coronary arteries to determine the need for a stent or if a patient can be treated medically. 

Technology | FFR Technologies | March 06, 2019
March 5, 2019 –  The U.S.
CathWorks FFRangio System Receives U.S. FDA Clearance
Technology | FFR Technologies | December 21, 2018
CathWorks announced that its FFRangio System received U.S. Food  and Drug Administration (FDA) 510(k) clearance. The...
The late-breaking FAST-FFR Trial demonstrated that the sensitivity and specificity of the CathWorks FFRangio angiography imaging derived fractional flow reserve (FFR-angio) technology matched the performance of wire-based FFR measurements. #TCT2018

The late-breaking FAST-FFR Trial demonstrated that the sensitivity and specificity of the CathWorks FFRangio angiography imaging derived fractional flow reserve (FFR-angio) technology matched the performance of wire-based FFR measurements.

News | FFR Technologies | October 04, 2018
October 4, 2018 — The late-breaking FAST-FFR Trial demonstrated that the sensitivity and specificity of the CathWorks
SCAI and the European Society of Cardiology recently added iFR to their guidelines.

An illustration of Philip’s iFR technology, showing the iFR pressure readings and a fusion angio image indicating pressure drops in the vessel during wire pull back. SCAI and the European Society of Cardiology recently added iFR to their guidelines.

Feature | FFR Technologies | September 05, 2018 | Dave Fornell, Editor
The use of invasive, pressure wire-based fractional flow reserve (FFR) in the cath lab is now considered the gold sta
European Society of Cardiology Incorporates iFR Technology Into Updated Revascularization Guidelines
News | FFR Technologies | August 29, 2018
Philips announced that the European Society of Cardiology (ESC) has incorporated instantaneous wave-free ratio (iFR)...
iFR reference numbers posted for new users in the cath lab at Northwestern Medicine's Central DuPage Hospital in Winfield, Ill.
News | FFR Technologies | July 26, 2018
July 26, 2018 — The Society of Cardiac Angiography and Interventions (SCAI) released a focused update expert consensu
CathWorks Receives CPT Code for Non-invasive FFRangio Measurements During PCI
News | FFR Technologies | July 12, 2018
CathWorks announced the approval of a new Current Procedural Terminology (CPT) code 0523T for non-invasive, 3-D...
Overlay Init